Clinical Trial Update: PD-L1 ImagiNg to prediCt Durvalumab Treatment Response in HNSCC [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating PD-L1 imaging to predict Durvalumab response in head and neck cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer

Drugs mentioned

• Durvalumab (durvalumab)

Snippet

Sponsor: Radboud University Medical Center | Conditions: Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED